ASH 2014

ASH 2014
The 56th ASH Annual Meeting & Exposition takes place in San Francisco, California at the Moscone Center from Decembr 6-9, 2014. It is the premier event in malignant & non-malignant hematology. Check back at this page for conference coverage and updates.
December 09, 2014
Monday's oral abstract sessions on multiple myeloma at the Annual Meeting of the American Society of Hematology featured final phase 1b/2 results on the elotuzumab combination that received breakthrough therapy status from FDA earlier this year.
December 09, 2014
Pomalidomide was approved by FDA in February 2013 for multiple myeloma patients whose disease has progressed despite having received at least 2 other therapies. On Monday, researchers at the American Society of Hematology Annual Meeting presented results of phase 2 studies on combinations with the immunomodulatory drug.
December 09, 2014
On the second day of the 56th Annual Meeting of the American Society of Hematology, held December 6-9 in San Francisco, a session on tyrosine kinase inhibitors in treating chronic myelogenous leukemia included 5-year follow-up results from the DASISION trial and recognizing failure for major molecular response to guide treatment modification.
December 08, 2014
At an education session at the American Society of Hematology Annual Meeting, Christopher R. Flowers, MD, MS, discussed current thinking in the use of routine imaging for patients who have achieved a long-term complete response in non-Hodgkin lymphoma.
December 08, 2014
The plenary session on the second day of the 56th Annual Meeting of the American Society of Hematology, held December 6-9 in San Francisco, saw the best presentations, selected by the Program Committee, from among the thousands of scientific abstracts that were accepted for the meeting. These talks included a JAK/STAT-mediated thrombopoietin regulation by the Ashwell-Morell receptor, lenalidomide-mediated casein kinase regulation in myelodysplastic syndrome, and the results of the SORAML trial in acute myeloid leukemia.
December 08, 2014
A novel treatment method unveiled at the 56th Annual Meeting of the American Society of Hematology was among 4 important studies about reducing blood clots presented Sunday at the gathering in San Francisco.
December 07, 2014
Saturday's poster session on Health Services and Outcomes research featured results projecting an overall reduction in medical costs from the use of new oral anticoagulants, and new studies about the treatment of children with sickle cell disease.
December 07, 2014
Jesus F. San Miguel, MD, PhD, of the Spanish Myeloma Group, delivered the Han-Wasserman Lecture and discussed prognostic factors that allowed his research team to give early treatment to high-risk patients, improving their survival.
December 07, 2014
While medical oncologists, drug developers, and research scientists presented their research findings and novel treatment options in hematological cancers, a special session in the afternoon on the first day of the 56th Annual Meeting of the American Society of Hematology (ASH), held December 6 to 9 in San Francisco, addressed the aspect of cost of care and the increasing financial burden faced by the cancer patient.
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.